Please login to the form below

Not currently logged in
Email:
Password:

asfotase alfa

This page shows the latest asfotase alfa news and features for those working in and with pharma, biotech and healthcare.

Amgen takes aim at Alexion’s patents for Soliris

Amgen takes aim at Alexion’s patents for Soliris

Alexion’s other products such as lysosomal acid lipase deficiency treatment Kanuma (sebelipase alfa) and Strensiq (asfotase alfa) for hypophosphatasia have a long way to go before they bring in enough

Latest news

  • Alexion adds to pipeline rebuild with $855m Wilson buy Alexion adds to pipeline rebuild with $855m Wilson buy

    A $1bn purchase of Enobia in 2011 gave it an enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP) - Strensiq (asfotase alfa) - which made $340m in sales last year but still ... However, its 2015 takeover of Synageva for $8.4bn has been less

  • NICE broadens access to Alexion's rare disease drug Strensiq NICE broadens access to Alexion's rare disease drug Strensiq

    New draft guidance from NICE means that the wider population of infants with HPP - not just those with the most severe form - will be eligible for treatment with Strensiq (asfotase alfa), ... NICE also turned down Alexion's other new enzyme replacement

  • NICE blocks second Alexion rare disease drug in a week NICE blocks second Alexion rare disease drug in a week

    The verdict comes just days after the agency excluded two patient groups in its final determination on rare bone disorder drug Strensiq (asfotase alfa), giving the go-ahead only for perinatal- ... Throughout this extremely complicated evaluation we have

  • AZ, BMS and Boehringer among UK Prix Galien finalists AZ, BMS and Boehringer among UK Prix Galien finalists

    Janssen. MCL, CLL, WM. sebelipase alfa. Kanuma. Alexio. Lysosomal acid lipase deficiency (LAL-D). ... asfotase alfa. Strensiq. Alexion. paediatric-onset hypophosphatasia (HPP) - bone manifestations. Real World Evidence Award 2016 finalists.

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    These were Kanuma (sebelipase alfa), the first-ever treatment for the rare, inherited disorder lysosomal acid lipase deficiency - and Strensiq (asfotase alfa), the first enzyme replacement therapy for patients with infantile- ... Alkermes. USA. asfotase

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...